Mukund Paravasthu insider trades: NovoCure (NVCR) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mukund reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | NVCR | ↓ Sell | 48,623 | $13.72 | $667K | Direct | Mar 5, 2026 (0d) |
| May 3, 2025 | NVCR | ↓ Sell | 592 | $17.91 | $11K | Direct | May 5, 2025 (2d) |
| Mar 3, 2025 | NVCR | ↓ Sell | 250 | $18.54 | $5K | Direct | Mar 4, 2025 (1d) |
| Feb 28, 2025 | NVCR | ↓ Sell | 2,014 | $19.71 | $40K | Direct | Mar 3, 2025 (3d) |
| Jan 11, 2025 | NVCR | ↓ Sell | 2,160 | $26.81 | $58K | Direct | Jan 15, 2025 (4d) |
| Nov 2, 2024 | NVCR | ↓ Sell | 44 | $16.69 | $734 | Direct | Nov 6, 2024 (4d) |
| Nov 1, 2024 | NVCR | ↓ Sell | 160 | $15.88 | $3K | Direct | Nov 4, 2024 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NVCR insiders
Open-market trades in the last 12 months
About Mukund Paravasthu's insider trades
Mukund Paravasthu is Chief Operating Officer at NovoCure (NVCR). Since Nov 1, 2024, Mukund has reported no open-market purchases and 7 sales worth $783K on SEC Form 4. In the last 12 months: 1 sale ($667K).
Their filings also include grants and awards (3 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NVCR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.